Patient-reported outcomes following selpercatinib treatment in Chinese patients with advanced RET fusion-positive non-small-cell lung cancer and thyroid cancer, and RET -mutant medullary thyroid cancer in the phase II LIBRETTO-321 trial.

Shun LuXiangqian ZhengYuping SunDingzhi HuangLin WuQinghai JiChengzhi ZhouJianying ZhouYe GuoMinghua GeDing DingJingxin ShaoWanli ZhangMing GaoYing Cheng

Published in: Therapeutic advances in medical oncology (2023)

This study was registered at ClinicalTrials.gov (https://clinicaltrials.gov/ct2/show/NCT04280081) ClinicalTrials.gov Identifier: NCT04280081.

Keyphrases

phase ii
patient reported outcomes
clinical trial
open label
phase iii
computed tomography
placebo controlled
study protocol
contrast enhanced
magnetic resonance
combination therapy
dual energy
wild type